Sou Hu Cai Jing·2025-08-20 10:53Company Overview - Beijing Zhaoyan New Drug Research Center Co., Ltd. primarily engages in non-clinical safety evaluation services for drugs, preclinical research services, and sales of laboratory animals and related products [1] - The main products include non-clinical research services, clinical services, and supply of experimental models [1] Financial Performance - For Q1 2025, the company reported revenue of 287 million yuan, a year-on-year decrease of 11.54% [1] - The net profit for the same period was 41.12 million yuan, showing a significant year-on-year increase of 115.11% [1] - The sales gross margin stood at 28.61% [1] Market Position - As of August 20, the company's stock closed at 31.14 yuan, down 3.26%, with a rolling PE ratio of 60.24 times [1] - The total market capitalization is 23.339 billion yuan [1] - In terms of industry comparison, the average PE ratio for the medical services sector is 49.21 times, with a median of 65.65 times, placing Zhaoyan New Drug at the 28th position in the industry [1][2] Institutional Holdings - As of Q1 2025, 17 institutions hold shares in Zhaoyan New Drug, all of which are funds, with a total holding of 10.9687 million shares valued at 231 million yuan [1]